Giftshed
2 known investors
Find your way into Giftshed
Giftshed builds a single-cell cancer data platform that images billions of cells from whole blood, uses Vision AI and robotics to detect and isolate rare circulating tumor cells, and applies single-cell RNA sequencing and multi-omics to guide precision cancer therapy. The platform is aimed at personalized cancer diagnostics and metastatic biology research.
Also known as Giftshed Inc.
Investors · 2
Company profile
researched Aug 2026Giftshed Inc. develops a single-cell cancer data platform intended to support therapy decisions in oncology. The company describes its approach as "Liquid Biopsy 2.0": an AI-native platform that images cells directly from whole blood and identifies ultra-rare circulating tumor cells (CTCs), which the company frames as the starting point of metastasis and as too rare to be reliably detected by conventional methods.
The platform combines three components. Robotics image billions of cells directly from whole blood, generating large-scale morphological datasets at single-cell resolution, with the company citing more than 5,000,000,000 cells per sample. An integrated Vision AI layer analyzes cellular morphology at scale to detect and drive the isolation of rare CTCs. Isolated CTCs are then processed for downstream single-cell RNA sequencing and multi-omics analysis to study metastatic biology and gene expression. The stated aim is to convert circulating tumor cells into data physicians can use to guide precision cancer therapy and monitor cancer in real time.
Founding story
The company was founded by Dongyoung Lee, PhD, who serves as Founder and CEO and is described as a serial biotech founder previously at Noul, a KOSDAQ-listed company, with 70+ global patents. Lee states that Giftshed is his second venture and that he chose to focus on metastatic cancer as the stage responsible for most cancer deaths.
▸Full profile — market position, technology, go-to-market
Market position
Giftshed positions its offering as a next-generation liquid biopsy approach, contrasting its single-cell imaging and AI-based CTC isolation with conventional detection methods that it describes as unable to reliably identify these rare cells.
Technology
The technology stack consists of robotic imaging of whole blood at true single-cell resolution, a Vision AI system that analyzes cell morphology at scale to detect and isolate ultra-rare circulating tumor cells, and downstream single-cell RNA sequencing and multi-omics processing of the isolated cells for analysis of metastatic biology and gene expression.
Go-to-market
The platform is oriented toward physicians making cancer therapy decisions and toward research into metastatic biology at cellular resolution.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 4
primary sources listed
- Giftshedgiftshed.bio · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Giftshed do?
- Giftshed is a single-cell cancer data company detecting and isolating circulating tumor cells from whole blood.
- Who are Giftshed's investors?
- Giftshed's investors include FuturePlay, Kakao Ventures.